KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Inventory (2016 - 2025)

Historic Inventory for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $4.9 billion.

  • AbbVie's Inventory rose 1096.63% to $4.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year increase of 1096.63%. This contributed to the annual value of $4.2 billion for FY2024, which is 200.05% up from last year.
  • AbbVie's Inventory amounted to $4.9 billion in Q3 2025, which was up 1096.63% from $5.0 billion recorded in Q2 2025.
  • AbbVie's Inventory's 5-year high stood at $5.0 billion during Q2 2025, with a 5-year trough of $3.1 billion in Q3 2021.
  • In the last 5 years, AbbVie's Inventory had a median value of $4.0 billion in 2023 and averaged $3.9 billion.
  • The largest annual percentage gain for AbbVie's Inventory in the last 5 years was 7744.03% (2021), contrasted with its biggest fall of 1658.04% (2021).
  • Over the past 5 years, AbbVie's Inventory (Quarter) stood at $3.1 billion in 2021, then increased by 14.42% to $3.6 billion in 2022, then rose by 14.53% to $4.1 billion in 2023, then grew by 2.0% to $4.2 billion in 2024, then grew by 18.11% to $4.9 billion in 2025.
  • Its last three reported values are $4.9 billion in Q3 2025, $5.0 billion for Q2 2025, and $4.5 billion during Q1 2025.